<SEC-DOCUMENT>0000899243-17-013902.txt : 20170519
<SEC-HEADER>0000899243-17-013902.hdr.sgml : 20170519
<ACCEPTANCE-DATETIME>20170519160816
ACCESSION NUMBER:		0000899243-17-013902
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170518
FILED AS OF DATE:		20170519
DATE AS OF CHANGE:		20170519

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prothena Corp plc
		CENTRAL INDEX KEY:			0001559053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ADELPHI PLAZA
		STREET 2:		UPPER GEORGE'S STREET
		CITY:			DUN LAOGHAIRE, CO. DUBLIN
		STATE:			L2
		ZIP:			A96 T927
		BUSINESS PHONE:		011-353-1-236-2500

	MAIL ADDRESS:	
		STREET 1:		ADELPHI PLAZA
		STREET 2:		UPPER GEORGE'S STREET
		CITY:			DUN LAOGHAIRE, CO. DUBLIN
		STATE:			L2
		ZIP:			A96 T927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neotope Corp Ltd
		DATE OF NAME CHANGE:	20120926

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Harfstrand Karl Anders Olof
		CENTRAL INDEX KEY:			0001646451

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35676
		FILM NUMBER:		17857879

	MAIL ADDRESS:	
		STREET 1:		C/O PROTHENA BIOSCIENCES INC
		STREET 2:		650 GATEWAY BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-05-18</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001559053</issuerCik>
        <issuerName>Prothena Corp plc</issuerName>
        <issuerTradingSymbol>PRTA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001646451</rptOwnerCik>
            <rptOwnerName>Harfstrand Karl Anders Olof</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PROTHENA BIOSCIENCES INC</rptOwnerStreet1>
            <rptOwnerStreet2>331 OYSTER POINT BOULEVARD</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>56.23</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2017-05-18</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>12000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2027-05-18</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>12000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>12000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2018 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ A.W. Homan, as Attorney-in-Fact for Karl Anders O. Harfstrand</signatureName>
        <signatureDate>2017-05-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
